Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs

Blood

Volumn 103, Issue 5, 2004, Pages 1855-1861

  Jones, Dylan T ^a   Addison, Elena ^a   North, Janet M ^a   Lowdell, Mark W ^a   Hoffbrand, A Victor ^a   Mehta, Atul B ^a   Ganeshaguru, Kanagasabai ^a   Folarin, Najeem I ^a   Wickremasinghe, R Gitendra ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYTOTOXIC AGENT; FLUDARABINE; GELDANAMYCIN; GLUCOSE REGULATED PROTEIN; GLUCOSE REGULATED PROTEIN 78; GRP94 PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HERBIMYCIN A; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL KILLING; CELL PROTECTION; CHRONIC LYMPHATIC LEUKEMIA; DOSE RESPONSE; DOWN REGULATION; FEMALE; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UPREGULATION;

EID: 1442356824     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1603     Document Type: Article

References (51)

1. Kipps TJ. Chronic lymphocytic leukaemia. Curr Opin Hematol. 1998;5:244-253.
2. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukaemia: a bird of a different feather. J Clin Oncol. 1999;17:399-408.
3. Kipps TJ. Chronic lymphocytic leukaemia. Curr Opin Hematol. 2000;7:223-234.
4. H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
5. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
6. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B cell receptor signal in chronic lymphocytic leukaemia. Blood. 2002;100:4609-4614.
7. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukaemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944-4951.
8. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable region mutations in chronic lymphocytic leukaemia. N Engl J Med. 2003;348:1764-1775.
9. Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukaemia. Leukemia. 2002;16:1015-1027.
10. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow up of patients with chronic lymphocytic leukaemia (CLL) receiving fludarabine regimes as initial therapy. Blood. 1998;92:1165-1171.
11. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukaemia. N Engl J Med. 2000;343:1750-1757.
12. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infection in patients with chronic lymphocytic leukaemia treated with fludarabine. Ann Intern Med. 1998;129:559-566.
13. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxystaurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukaemia. Blood. 2000;96:393-397.
14. Chandra J, Niemer I, Gilbreath J, et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood. 1998;92:4220-4229.
15. Masdehors P, Merle-Beral H, Maloum K, Omura S, Magdelenat H, Delic J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood. 2000;96:269-274.
16. Pepper C, Thomas A, Hoy T, Milligan D, Bentley P, Fegan C. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase and suppression of ERK activity in B-cell chronic lymphocytic leukaemia cells in vitro. Blood. 2003;101:2454-2460.
17. Pederson IM, Kitada S, Schimmer A, et al. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood. 2002;100:2965-2972.
18. Moon EY, Lerner A. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukaemia cells that is regulated by protein phosphatase 2A. Blood. 2003;101:4122-4130.
19. Philippousis F, Arguin C, Mateo V, Steff A-M, Hugo P. Monoglycerides induce apoptosis in human leukemic cells while sparing normal peripheral blood mononuclear cells. Blood. 2003;101:292-294.
20. Sarfati M, Mateo V, Baudet S, et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukaemia cells. Blood. 2003;101:265-269.
21. Byrd JC, Lucas DM, Mone A, Kitner JB, Drabick JJ, Grever MR. KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukaemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Blood. 2003;101:4547-4550.
22. Anether G, Tinhofer I, Senfter M, Greil R. Tetrocarcin-A-induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2-independent pathway. Blood. 2003;101:4561-4568.
23. Ganeshaguru K, Wickremasinghe RG, Jones DT, et al. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukaemia cells in vitro. Haematologica. 2002;87:167-176.
24. Grever MR. In pursuit of a complete remission: exploring novel therapeutic agents in CLL. Blood. 2003;101:2449.
25. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994;84:3148-3157.
26. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85:1580-1589.
27. Bullrich F, Rasio D, Kitada S, et al. ATM mutations in B-cell chronic lymphocytic leukaemia. Cancer Res. 1999;59:24-27.
28. Starostik P, Manshouri T, O'Brien S, et al. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res. 1998;58:4552-4557.
29. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001;98:814-822.
30. H mutation in chronic lymphocytic leukemia. Blood. 2002;100:1404-1409.
31. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 2002;8: S55-S61.
32. Sausville EA. Combining cytotoxics and 17-allylamino 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res. 2001;7:2155-2158.
33. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A. 1994;91:8324-8328.
34. Chavany C, Mimnaugh E, Miller P, et al. p185erbB2 binds to GRP94 in vivo: dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem. 1996;271:4974-4977.
35. Lawson B, Brewer J, Hendershot LM. Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway. J Cell Physiol. 1998;174:170-178.
36. Kaufman RJ. Stress signalling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev. 1999;13:1211-1233.
37. Patil C, Walter P. Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals. Curr Opin Cell Biol. 2001;13:349-355.
38. Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol. 2001;3: E255-E263.
39. Binet JL, Auquier A, Dighiero, G, et al. A new prognostic classification of chronic lymphocytic leukaemia derived from a multivariate survival analysis. Cancer. 1981;48:198-206.
40. Jones DT, Ganeshaguru K, Folarin NI et al. Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs and γ radiation. Blood. 2001;98:2800-2807.
41. Twentyman PR, Fox NE, Rees JK. Chemosensitivity testing of fresh leukemia cells using the MTT colorimetric assay. Br J Haematol. 1989;71:19-24.
42. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
43. Wuchter C, Krappmann D, Cai Z, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukaemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia. 2001;15:921-928.
44. Posovszky C, Friesen C, Herr I, Debatin KM. Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T lymphocyte-mediated apoptosis. Leukemia. 1999;13:400-409.
45. Sutherland HJ, Eaves AC, Eaves CJ. Quantitative assays for human hematopoietic progenitor cells. In: Gee AP, ed. Bone Marrow Processing and Purging: A Practical Guide. Boca Raton, FL: CRC Press; 1991:155-171.
46. Jones DT, Ganeshaguru K, Anderson RJ, et al. Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukaemia cells from chlorambucil- and radiation-induced apoptosis. Blood. 2003;101:3174-3180.
47. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-27-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001;61:1799-1804.
48. Beere HM, Wolf BB, Cain K, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol. 2000;2:469-475.
49. Rao RV, Peel A, Logvinova A, et al. Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. FEBS Lett. 2002;514:122-128.
50. Kelland LR, Sharp SY, Rogers PM, Myers T, Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino 17-demethoxygeldanamyin, an inhibitor of heat shock protein 90. J Natl Cancer Inst. 1999;91:1940-1949.
51. Chiosis G, Lucas B, Shtil A, Huezzot H, Rosen N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem. 2002;10:3555-3564.